Read over every page. As optimistic as ever. CitiGroup has taken a nearly 10% stake since last report. All 3 Phase 2 trials in ASH, PNAFLD, and C.Diff. reading out in early 2019. Arun Sanyal believes in the company and IMM-124E for liver disease inflammation. The compound has broad therapeutic effect across so many GI diseases, liver disease, colitis, IBD, C.Diff, Shigella, ETEC, you nam
e it. Take a look at the preclinical C.Diff. results. They are incredible. Best I have ever seen to be honest. So excited about that readout. Potential value of company: C.Diff = $300M, Shigella = $200M, liver disease therapeutics = $500M to $1B, IBD = $300-$500M. Trades at $35M USD market cap. This ride is going to be so much fun
IMC Price at posting:
33.5¢ Sentiment: Buy Disclosure: Held
